Fundamental Analysis of EYENOVIA INC(NASDAQ:EYEN) stock

Fundamental Rating

EYEN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EYEN have multiple concerns. While showing a medium growth rate, EYEN is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

EYEN had negative earnings in the past year.

EYEN had a negative operating cash flow in the past year.

EYEN had negative earnings in each of the past 5 years.

In the past 5 years EYEN always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -94.75%, EYEN is doing worse than 80.00% of the companies in the same industry.

With a Return On Equity value of -303.00%, EYEN is not doing good in the industry: 78.46% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-94.75%
ROE	-303%
ROIC	N/A

ROA(3y)-75.11%

ROA(5y)-85.52%

ROE(3y)-175.98%

ROE(5y)-167.48%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EYEN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EYEN does not have a ROIC to compare to the WACC, probably because it is not profitable.

EYEN has more shares outstanding than it did 1 year ago.

The number of shares outstanding for EYEN has been increased compared to 5 years ago.

EYEN has a worse debt/assets ratio than last year.

2.2 Solvency

EYEN has an Altman-Z score of -8.55. This is a bad value and indicates that EYEN is not financially healthy and even has some risk of bankruptcy.

EYEN has a worse Altman-Z score (-8.55) than 71.79% of its industry peers.

A Debt/Equity ratio of 1.00 indicates that EYEN is somewhat dependend on debt financing.

The Debt to Equity ratio of EYEN (1.00) is worse than 74.36% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1
Debt/FCF	N/A
Altman-Z	-8.55

ROIC/WACCN/A

WACC10%

2.3 Liquidity

EYEN has a Current Ratio of 2.17. This indicates that EYEN is financially healthy and has no problem in meeting its short term obligations.

EYEN has a Current ratio of 2.17. This is in the lower half of the industry: EYEN underperforms 64.10% of its industry peers.

EYEN has a Quick Ratio of 2.16. This indicates that EYEN is financially healthy and has no problem in meeting its short term obligations.

EYEN's Quick ratio of 2.16 is in line compared to the rest of the industry. EYEN outperforms 42.56% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.17
Quick Ratio	2.16

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EYEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.24%, which is quite impressive.

Measured over the past years, EYEN shows a very negative growth in Revenue. The Revenue has been decreasing by -87.63% on average per year.

EPS 1Y (TTM)20.24%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-5.88%

Revenue 1Y (TTM)N/A

Revenue growth 3Y-87.63%

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

EYEN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.15% yearly.

Based on estimates for the next years, EYEN will show a very strong growth in Revenue. The Revenue will grow by 217.08% on average per year.

EPS Next Y-5.5%

EPS Next 2Y-1.75%

EPS Next 3Y6.96%

EPS Next 5Y26.15%

Revenue Next Year1117.28%

Revenue Next 2Y451.17%

Revenue Next 3Y333.69%

Revenue Next 5Y217.08%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

EYEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year EYEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-1.75%

EPS Next 3Y6.96%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EYEN does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EYENOVIA INC

NASDAQ:EYEN (4/26/2024, 7:00:02 PM)

After market: 0.64 +0.01 (+1.88%)

0.6282

-0.08 (-11.68%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap32.01M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-94.75%
ROE	-303%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	1
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.17
Quick Ratio	2.16
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)20.24%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-5.5%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3Y-87.63%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

EYENOVIA INC (EYEN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens